Depression is one of the most common and most devastating mental health conditions in the world. For many people, it responds to antidepressants and psychotherapy. But for a substantial minority — estimates range from 30 to 50 percent of people diagnosed with major depressive disorder — first-line treatments provide inadequate relief. Treatment-resistant depression is not a failure of willpower or effort. It is a medical reality that demands different tools. Ketamine has emerged as one of the most significant of those tools in decades, and understanding what the research actually shows — as opposed to what the hype suggests — is essential for anyone considering it.

How Ketamine Differs from Standard Antidepressants

Standard antidepressants — SSRIs, SNRIs, tricyclics — primarily target monoamine neurotransmitters: serotonin, norepinephrine, dopamine. They typically require four to six weeks before meaningful symptom relief appears, and many patients cycle through multiple medications over years before finding something that works adequately. Ketamine operates through a fundamentally different mechanism. It is an NMDA receptor antagonist, meaning it blocks glutamate receptors in the brain. Glutamate is the brain's primary excitatory neurotransmitter, and its dysregulation has been implicated in depression in ways that the monoamine hypothesis does not capture. Ketamine's blockade of NMDA receptors triggers a rapid cascade of changes, including a surge in BDNF (brain-derived neurotrophic factor), a protein involved in neuroplasticity — the brain's ability to form new connections. The practical result is striking: many patients report significant reduction in depressive symptoms within hours to days of a ketamine infusion, rather than weeks. For people who are acutely suicidal, this speed matters enormously.

What the Clinical Evidence Shows

The evidence base for ketamine in treatment-resistant depression is substantial and growing. Research from Yale School of Medicine, where much of the foundational work was done, established that intravenous ketamine produced rapid antidepressant effects in patients who had failed multiple prior treatments. Subsequent trials have consistently replicated this finding across different populations and settings. Esketamine, a nasal spray form of ketamine's S-enantiomer marketed as Spravato, received FDA approval in 2019 specifically for treatment-resistant depression and major depressive disorder with active suicidal ideation. This approval was based on multiple placebo-controlled trials showing significant symptom reduction. A 2020 multicenter trial published in the American Journal of Psychiatry found that esketamine combined with a newly initiated oral antidepressant significantly delayed relapse in patients who had achieved remission — one of the first studies to address the durability question. Research from Stanford University's Depression Research Clinic has investigated the neurobiological mechanisms underlying ketamine's effects, identifying synaptogenesis — the formation of new synaptic connections in prefrontal and limbic regions — as a key component of sustained antidepressant response. This finding shifts the understanding of ketamine from a simple receptor blocker to a neuroplasticity catalyst.

The Durability Problem

The most significant limitation of ketamine treatment is that its effects are often temporary. A single infusion may produce dramatic symptom relief that lasts days to weeks, after which depression returns. Maintenance protocols — repeated infusions at regular intervals — can extend the benefit, but the optimal frequency and duration remain under active investigation. This temporariness is sometimes presented as a disqualifying flaw. That framing deserves scrutiny. Many accepted psychiatric treatments require ongoing use — antidepressants work while you take them and often need to be continued indefinitely for relapse prevention. The more accurate framing for ketamine is that it is a powerful tool for acute treatment and crisis stabilization, often most effective when combined with ongoing psychotherapy that uses the window of neuroplasticity ketamine creates.

Side Effects and Safety

Ketamine is not without risks. During infusion, patients commonly experience dissociative effects — a sense of unreality, perceptual distortion, sometimes vivid imagery. These effects resolve as the drug metabolizes, typically within an hour. Blood pressure elevation during infusion is monitored. The dissociative experience ranges from unsettling to profound depending on the person and the set and setting. The question of misuse potential deserves honest acknowledgment. Ketamine has a history as a recreational drug, and concerns about bladder toxicity and psychological dependence are legitimate in the context of heavy recreational use. In clinical settings with appropriate dose control and monitoring, these risks are substantially mitigated — but patients with substance use histories warrant careful evaluation before ketamine treatment. A note worth raising: some practitioners in the psychedelic-assisted therapy movement have integrated ketamine with psychotherapeutic frameworks, using the dissociative state as a context for therapeutic processing. This approach, sometimes called ketamine-assisted psychotherapy, is distinct from infusion clinics focused purely on biological symptom relief. The evidence for the combined approach is promising but less developed than the evidence for ketamine alone.

The Bottom Line

Ketamine offers something genuinely new in psychiatry: fast-acting relief for people who have exhausted standard options. It is not a cure, and it is not appropriate for everyone. But for treatment-resistant depression, especially with active suicidal ideation, the evidence supports its use as a meaningful intervention — one that has given significant relief to people who had stopped expecting any.